01/05/2026
EW ARTICLE:
IVERM€CTIN and F€NBEND@ZOLE Testimonial – 68 year old Louisiana woman with Stage 3 Endometri@l C@nc€r operated, reports after 3 months: residual disease eliminated with NO ch€mo!
🚨 TRIGGER WARNING!!
No ch€mo, no r@di@tion, no conventional Onc0l0gy involved here!! 😱
These are the stories Big Pharma bots avoid like the plague — because they can’t say “it was ch€mo.”
STORY:
68 year old Louisiana woman with Stage 3 Endometri@l C@nc€r
Operated Jun.23, 2025 (hysterectomy)
In September 2025 she started:
IVERM€CTIN 1mg/kg/day
F€NBEND@ZOLE 1100mg/day
Results after 3 months:
CA125:
77 (pre-op) → 20 (post-op) → 6 → 5
SIGNATERA (ctDNA):
0.05 (post-op Aug.22) → 0.00
PET/CT:
Right inguinal lymph node m€t 1.5cm SUV 9.1 (Aug.27)
→ 1.0cm SUV 2.1 (Dec.10)
(typically called normal by radiologists)
KEY POINTS:
• Stage 3 Endometri@l C@nc€r patient had a small amount of residual disease after hysterectomy in June 2025.
• She took no ch€mo, no r@di@tion, no immun0th€r@py, no conventional treatment after surgery.
• After 3 months of Iverm€ctin + Fenbend@zole, residual disease resolved completely, confirmed by CA125, SIGNATERA (circulating tumor DNA), and PET/CT 😱
Mainstream Onc0l0gy tells us this is IMPOSSIBLE.
This completely upends the modern theory of C@nc€r care — where patients with minimal residual disease are still pushed into toxic treatments “just in case.”
We are revolutionizing C@nc€r research and C@nc€r care.
Largest Iverm€ctin C@nc€r clientele in the world!
SEND A DIRECT MESSAGE TO GET STARTED
